Distinct ventures.
Shared purpose.

MyFlorence is being developed to bring fragmented health information into a clearer, patient-directed view. The focus is preparation, understanding, and continuity between care encounters.

Public product access is being prepared. It is not a substitute for diagnosis, treatment, or a clinician’s judgment.

CashCare explores a more direct path between people seeking care and providers offering clearly scoped, cash-pay services. Price transparency and useful service information are central to the product.

Marketplace development is underway. This page does not offer care, booking, or payments. CashCare remains standalone and non-PHI.

OncologyIT brings the evaluation of AI into the context of oncology practice, helping cancer-care teams examine capabilities, limits, and the decisions that need human review.

Educational content is not clinical advice. No CME credit or professional certification is implied.

HealthIT is a research resource for people evaluating healthcare AI products, vendor claims, and implementation choices. It connects practical questions with source material and evidence.

Research is for evaluation and education. Product listings do not constitute an endorsement or evidence of clinical validation.

OncoTech AI examines how AI is changing healthcare: clinical workflows, infrastructure, market dynamics, and the consequences for patients and professionals.

Commentary and analysis are distinct from clinical advice and individual product recommendations.

Lumen is the portfolio’s cancer-focused education and intelligence initiative. The public offering and its relationship to the broader educational portfolio continue to be developed.

No accreditation, clinical service, or enrollment availability is implied.

Veracausa is developing a service approach to exposure and causation analysis, grounded in medical reasoning and source documentation.

This is a portfolio introduction, not an offer of legal advice or an invitation to submit case records.